Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Gilead Sciences, Inc.Trade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Gilead Sciences, Inc. trades at $136.86 (market cap $168.35B), while Charles Schwab Corporation Common Stock trades at $108.64 (market cap $186.25B). The key difference: Gilead Sciences, Inc. and Charles Schwab Corporation Common Stock are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

GILDSCHW
Market Cap
$168.35B$186.25B
Sector
HealthFinancials
52-Week High
$155.80$108.02
52-Week Low
$110.56$85.35
Enterprise Value
$191.42B
Dividend Yield
2.42%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $108.63, up 0.59% today, approaching its all-time high of $109.05. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. Revenue grew to $23.92B in 2025 with net income margin expanding to 38.79%. Recent news highlights institutional buying and positive analyst coverage, though an insider sale and ongoing litigation present minor concerns.

Outlook remains positive with analyst consensus target of $122.33 suggesting 12.6% upside. Strong earnings growth, improving cash flow trends, and market leadership position support further appreciation. Key risks include market sensitivity to interest rates, competitive pressures, and potential regulatory impacts from ongoing litigation. The stock offers growth potential but requires monitoring of macroeconomic conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW